Skip to content

Alkermes ALKS EV / EBITDA

EV / EBITDA at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
12×+0.4×
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
17.6×-4.0×
AbbVie logo
AbbVieABBV
19.8×
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
16.4×-5.2×
Arrowhead Research logo
Arrowhead ResearchARWR
27.4×
ALN
Alnylam PharmaceuticalsALNY
52.6×

Other financials

Income statement

See full
Revenue$392.9M+28.2%
Gross profit$331.3M+28.8%
Operating income-$48.3M-450%
Net income-$66.5M-396%
EPS (diluted)-$0.40-408%

Balance sheet

See full
Cash & equivalents$351.6M-12.1%
Total debt$1.6B+2,034%
Total equity$1.8B+15.9%
Total assets$4.3B+105%

Cash flow

See full
Operating cash flow-$165.7M-268%
CapEx$4.1M-59.5%
Free cash flow-$169.8M-291%

Valuation

See full
Market cap$7.5B+9.7%
Enterprise value$8.73B+41.2%
P/E49.1×+29.7×
P/S4.8×+0.3×

Profitability

See full
Gross margin86.6%+2.2pp
Operating margin12.3%-13.6pp
Net margin9.8%-13.5pp
FCF margin14.2%-17.6pp

Returns & leverage

See full
Return on equity9.4%-16.1pp
Debt / equity0.9×+0.9×
Current ratio2.3×-1.1×

Where this comes from

Calculated from Alkermes’s reported figures.

Based on the most recent quarter.

The official record: Alkermes’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alkermes's ev / ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Alkermes's EV / EBITDA?
Alkermes (ALKS) reported EV / EBITDA of 30.8× in Q1 2026.
How has Alkermes's EV / EBITDA changed year-over-year?
Alkermes's EV / EBITDA increased by 156.1% year-over-year, from 12× to 30.8×.
What is the long-term trend for Alkermes's EV / EBITDA?
Over 3 years (2021 to 2025), Alkermes's EV / EBITDA has grown at a -11.1% compound annual growth rate (CAGR), from 21.8× to 15.3×.
What does EV / EBITDA mean?
What the whole business (debt included) costs relative to its operating cash earnings.
How do you interpret EV / EBITDA?
Lets you compare companies with different leverage and tax positions on a like-for-like basis — the standard multiple in M&A. Lower can mean cheaper, subject to growth and capital intensity.
How does EV / EBITDA compare across companies?
Broadly comparable across non-financial sectors; not used for banks and insurers, where EBITDA is not meaningful.